Riluzole in the Treatment of Bipolar Depression

Autores
Categoría Estudio primario
Registro de estudiosclinicaltrials.gov
Año 2007

Este artículo no está incluido en ninguna revisión sistemática

Cargando información sobre las referencias
Bipolar disorder is a common and often chronic and debilitating mental illness. The depressive phase of bipolar disorder contributes the largest portion of the disorder, and treatment resistant bipolar depression represents a significant public health problem. Recent research has suggested that bipolar depression is associated with elevated brain glutamate activity. We hypothesize that riluzole, a drug approved for ALS which inhibits glutamate activity, will lead to clinical improvement in patients with bipolar depression.
Epistemonikos ID: 6256bc9bf6ca24f23d3e0a36f5e8f4a0cea0a484
First added on: May 04, 2024